New research shows how regular aspirin use can lower cancer risk, especially for those with unhealthy lifestyles. Discover ...

How can AI transform colorectal cancer care, and how can we ensure its adoption aligns with the NHS’s mission of delivering ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Colorectal Cancer.

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...

Leap Therapeutics focuses on developing DKN-01, a promising monoclonal antibody for solid tumors, with encouraging early ...

Korean researchers have developed a technology that treats colon cancer by converting cancer cells into a state resembling ...

In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting ...

God promises Abram, at the age of 99, that Sarah shall have a son (17:16,19; 18:10). God's Covenant with Abram embraced circumcision. God changes Abram to Abraham, meaning father of a multitude ...

The effects of signalling pathway modulators on the status of intestinal stem cell biology ... renewal are of the utmost interest because they are disrupted in conditions such as inflammatory bowel ...

The U.S. surgeon general issued a report that linked alcohol consumption to seven cancers and suggested that alcoholic ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral ...